Compare Enveric Biosciences Inc (ENVB) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Thomson Reuters Corp — how do they compare? Enveric Biosciences Inc trades at $1.37 (market cap $5.32M), while Thomson Reuters Corp trades at $99.88 (market cap $41.16B). The key difference: Thomson Reuters Corp is far larger — about 7736.8× Enveric Biosciences Inc's market cap, and Thomson Reuters Corp pays a 2.74% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TRI | |
|---|---|---|
Market Cap | $5.32M | $41.16B |
Sector | Health | Industrials |
52-Week High | $17.40 | $211.14 |
52-Week Low | $1.28 | $76.55 |
Enterprise Value | $408.82K | $43.12B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Thomson Reuters (TRI) trades at $100.30, up 9.33% in the past 24 hours, reflecting strong momentum. The stock shows a bullish technical signal with moving averages and ADX supporting upward trends, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 19.93% net income margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR for its global print business and continued AI integration, signaling strategic growth initiatives.
The outlook for TRI is positive, driven by analyst consensus favoring a Buy rating with a $129.96 price target, implying significant upside. Key opportunities lie in AI adoption and partnership expansions, but risks include execution challenges in technology transitions and potential revenue volatility. Investors should weigh strong fundamentals against near-term overbought technicals and competitive pressures in the information services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
